definiens: means any drug or biological product that is subject to review under anabbreviated approval pathway as a biosimilar, follow - on biologic or generic biological product, as those terms are commonly understood underthe FD&C Act or the PHS Act and related rules and regulations, or the corresponding or similar laws, rules and regulations of any otherjurisdiction which is sold by a Third Party that is not a sublicensee of NewCo ( or any of its Affiliates ) and that has not otherwise beenauthorized, directly or indirectly, by NewCo ( or any of its Affiliates ) to market and sell such product ; and(c ) [ * * * * * ] 8.6.5 Rights Following Expiration of Royalty Term . [ * * * * * ] ARTICLE 9FINANCIAL TERMS ; REPORTS ; AUDITS9.1 Timing of Royalty Payment . All royalty payments shall be made by NewCo to AFMD within [ * * * * * ] after receipt of an invoice therefor fromAFMD . AFMD shall invoice NewCo for all royalty payments owing to AFMD pursuant to the Net Sales Report provided by NewCo to AFMDfollowing the end of each calendar quarter pursuant to Section 9.2